Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Doxorubicin 4Gemcitabine 3pembrolizumab 2pazopanib 2fludarabine 2cixutumumab 2brostallicin 2Sorafenib 2Radiation Dose Hypofractionation 2Docetaxel 2Cyclophosphamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1tazemetostat 1sotigalimab 1soblidotin 1romidepsin 1reolysin 1perifosine 1pasireotide 1lorvotuzumab mertansine 1ixabepilone 1interferon gamma-1b 1exatecan 1durvalumab 1drozitumab 1atezolizumab 1Trastuzumab 1Trabectedin 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Synovial × Ipilimumab × Clear all
NCT00140855 2022-10-12

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Ludwig Institute for Cancer Research

Phase 2 Terminated
6 enrolled 8 charts
Sarcoma

Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡